AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03500731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD19 negative hematopoietic stem cells
Description: Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation
Study NCT03500731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Transplantation Conditioning
Study NCT03500731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Transplantation Conditioning
Study NCT03500731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Transplantation Conditioning
Study NCT03500731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Transplantation Conditioning
Study NCT03500731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Transplantation conditioning
Study NCT03500731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Transplantation Conditioning
Study NCT02944656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Participants in this group will receive 600 mg of gabapentin given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion. Gabapentin is an FDA approved medication that is used to prevent seizures and to treat various forms of chronic and acute pain.
Study NCT02944656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
Study NCT04631445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to \< 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).
Study NCT04205604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoro Dopa Imaging
Description: Imaging with 18F-Fluoro Dopa PET Imaging
Study NCT04158739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT
Study NCT02497963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foreskin Graft-Tubularized Incised Plate
Description: TIP Urethroplasty with foreskin graft in primary hypospadias
Study NCT02497963 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubularized Incised Plate
Description: TIP Urethroplasty without foreskin graft in primary hypospadias
Study NCT04158739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab
Description: Given IV
Study NCT02925182 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Er,Cr:YSGG Laser
Study NCT02925182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG Laser
Study NCT03078296 — intervention group
Intervention type: OTHER
Intervention: survey respondents
Description: all survey participants will be asked to complete a questionnaire
Study NCT02872974 — intervention group
Intervention type: OTHER
Intervention: GDM
Description: Exposure to GDM during fetal life
Study NCT01975571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear® Nucleus™ Hybrid L24
Description: The Nucleus Hybrid L24 cochlear implant incorporates an electrode array designed to preserve residual hearing. This has been accomplished by employing a thin, straight, intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The Nucleus Hybrid L24 array has 22 electrodes spread over 16 mm and an anticipated insertion depth of 16 mm. It is slim, with its dimensions ranging from 0.35 x 0.25 mm (at the tip) to 0.55 x 0.4 mm, and designed to minimize lateral wall forces with a stiffened basal section to prevent buckling. The resultant insertion angle is about 280-300° in the scala tympani for the Hybrid L24, as confirmed in temporal bone trials at the Medical University Hannover and the University of Melbourne.
Study NCT01975571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear® Nucleus™ Hybrid S12
Description: The Nucleus Hybrid S12 cochlear implant incorporates an electrode array designed to stimulate the high-frequency, basal region of the cochlea while maintaining useful acoustic hearing in the low-frequency, apical region. This has been accomplished by employing a short, thin, straight intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The electrode array incorporates a collar to prevent over-insertion, or further migration, into the cochlea beyond the point where the basal turn curves into the ascending segment. Thus, the electrode array is placed within the straight segment of the basal turn of the scala tympani via a cochleostomy.
Study NCT03545295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type 2
Description: Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, posterior to the Quadratus Lumborum muscle
Study NCT03862157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT03862157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study NCT03862157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03872284 — intervention group
Intervention type: OTHER
Intervention: oculomotor movement recordings, neurovisual assessment
Description: Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
Study NCT04371081 — intervention group
Intervention type: DEVICE
Intervention: Amplatzer Piccolo Occluder
Description: Interventional placement of vascular occluder
Study NCT03391960 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Passive disinfection device
Description: Add use of passive disinfection cap to existing central line needleless connector infection control procedure
Study NCT06766396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postpartum Intrauterine Contraceptive Device (PPIUCD).
Description: Participants in the intervention arm will receive a postpartum intrauterine contraceptive device (PPIUCD) immediately after delivery. For vaginal deliveries, the PPIUCD will be inserted manually using Kelly's forceps under aseptic conditions, while for cesarean deliveries, the device will be inserted before uterine incision closure. All insertions will be performed by trained healthcare professionals
Study NCT06764212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: M-mode ultrasonography images of the fascia under the trapezius muscle will be recorded during 3 different movements.
Study NCT06766084 — intervention group
Intervention type: PROCEDURE
Intervention: CABG
Description: All patients underwent isolated CABG and retrospectively followed to asses clinical outcomes of the two different revascularization techniques
Study NCT03545295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type 3
Description: Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, anterior to the Quadratus Lumborum muscle
Study NCT02222233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA delayed release (enteric coated) tablet
Study NCT02222233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA solution
Study NCT02222233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA particulate
Study NCT06767982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guerin (BCG)
Description: In this study we compared the efficacy and side effects of two different strains of BCG (RIVM and RUSSIAN strains) in non muscle invasive bladder cancer patients
Study NCT06768619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: single-dose of test formulation+single-dose of reference formulation
Description: Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
Study NCT06768619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: single-dose of reference formulation+single-dose of test formulation
Description: Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
Study NCT01648725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A short preanesthetic hypnosis before induction of anesthesia
Study NCT01648725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Standard care before induction of anesthesia
Study NCT02165189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Participants will be administered simeprevir capsule 150 mg orally once daily up to 12 weeks.
Study NCT02165189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
Study NCT02165189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will be administered ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram (\[kg\]) or 3 x 200 mg tablets (for participants weighing more than 75 kg) orally once daily up to 12 weeks.
Study NCT02165189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Participants will be administered simeprevir capsule 150 mg orally once daily up to 24 weeks.
Study NCT02165189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 24 weeks.
Study NCT01311375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: w3 supplement in SCI
Description: supplements(Mor DHA and Ca 500 mg -D200 micro g )( will be given in this group
Study NCT01311375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo+ capsule CA-D
Study NCT02162719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Participants received ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
Study NCT02162719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants received paclitaxel 80 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
Study NCT02162719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Participants received paclitaxel 80 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
Study NCT02162719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
Study NCT04180137 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovenous laser ablation of great saphenous vein (GSV) and microphlebectomy of varicose veins
Description: Surgical treatment is performed as endovenous laser ablation of GSV and microphlebectomy of varicose branches according to a standard protocol:~The intervention includes treatment of the pathological upright reflux and varicose veins. Ultrasound-guided GSV puncture at the upper third of the leg under local anesthesia. The light guide is inserted into the vein lumen and pushed through to the saphenofemoral junction. Under ultrasound guidance the light guide is positioned at v. epigastrica superficialis junction. Under ultrasound guidance tumescent anesthesia is produced around the GSV from puncture site up to the saphenofemoral junction. Laser coagulation (with radial light guide), linear energy density - 75 J/cm, automatic traction of the light guide at the speed 0.7 mm/sec. Varicose veins are resected through skin punctures using Varady hook 1-2 mm.
Study NCT04180137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation of great saphenous vein (GSV) and microphlebectomy of varicose veins
Description: Surgical treatment is performed as endovenous laser ablation of GSV and microphlebectomy of varicose branches according to a standard protocol:~The intervention includes treatment of the pathological upright reflux and varicose veins. Ultrasound-guided GSV puncture at the upper third of the leg under local anesthesia. The light guide is inserted into the vein lumen and pushed through to the saphenofemoral junction. Under ultrasound guidance the light guide is positioned at v. epigastrica superficialis junction. Under ultrasound guidance tumescent anesthesia is produced around the GSV from puncture site up to the saphenofemoral junction. Laser coagulation (with radial light guide), linear energy density - 75 J/cm, automatic traction of the light guide at the speed 0.7 mm/sec. Varicose veins are resected through skin punctures using Varady hook 1-2 mm.
Study NCT04180137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.
Study NCT01666743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
Study NCT01719913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High gluten
Description: Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
Study NCT01719913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low gluten
Description: Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
Study NCT03843541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg
Description: NAC will be administered twice a day, morning and evening, during treatment period.
Study NCT03843541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol hydrochloride 30 mg
Description: Ambroxol hydrochloride will be administered twice a day, morning and evening, during treatment period.
Study NCT03843541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered twice a day, morning and evening, during treatment period.
Study NCT02346747 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vigil
Description: The bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine, Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
Study NCT02346747 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To maintain placebo effect and eliminate bias due to volumetric differences, the number of Vigil doses manufactured from harvested tissue (except if below 4) will be used to guide manufacture of the same number of doses of placebo for each subject. Placebo will consist of freeze media \[10% DMSO (dimethyl sulfoxide; Cryoserv USP; Mylan Institutional USP), 1% Human Serum Albumin (ABO Pharmaceuticals) in Plasma-Lyte A, pH 7.4 (Baxter)\]. Depending upon randomization assignment, placebo or Vigil will be delivered in identical vials and drawn up in 'covered' syringes for intradermal injection.
Study NCT06768346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperthermia will be delivered in combination with each instillation using the Combat BRS system
Description: The Combat BRS system is a temperature controlled fluid recirculation system for the delivery of hyperthermic intravesical chemotherapy. The chemotherapy fluid is circulated in a closed system and warmed by an external isolated dry system using a novel innovative laminated aluminium foil heat exchanger with a small priming volume.
Study NCT02067455 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography
Study NCT02946450 — intervention group
Intervention type: DRUG
Intervention: Other: Not applicable-observational study
Study NCT03401840 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative hypofractionated stereotactic radiotherapy
Description: total dose of 36Gy in 6 fractions over 11-13 days
Study NCT04497844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Participants will receive Niraparib 200 mg once daily.
Study NCT00991029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
Study NCT00991029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Loading dose of 8 tablets followed by one tablet daily for 89 days
Study NCT02359578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
Study NCT02766010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TensorTip
Description: Non Invasive screening of various physiological and hematological parameters.
Study NCT01694069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product
Description: 400 mg/kg/day as either intermittent or continuous infusion
Study NCT01694069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam combination product
Description: 400 mg/kg/day as either intermittent or continuous infusion
Study NCT01514838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study NCT01514838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acarbose
Description: oral
Study NCT01514838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral, used only during placebo run-in period
Study NCT01514838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral, used only during placebo run-in period
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4345
Description: oral administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: oral or depot administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone
Description: oral or depot administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: oral administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: quetiapine
Description: oral administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Oral or depot administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: olanzapine
Description: Oral or depot administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone
Description: Oral or depot administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ziprasidone
Description: Oral or depot administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Oral or depot administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aripiprazole
Description: Oral or depot administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brexpiprazole
Description: Oral administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: brexpiprazole
Description: Oral administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone
Description: Oral or depot administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paliperidone
Description: Oral or depot administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurasidone
Description: Oral administration
Study NCT03557931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lurasidone
Description: Oral administration